Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) released its cash dividend proposal on 24 March 2026. The board declared a final ordinary dividend of RMB0.39 per share for the financial year ended 31 December 2025, pending shareholder approval at the forthcoming annual general meeting.

Key payment dates—including ex-dividend, record and distribution dates—will be announced once finalised. Tricor Investor Services Limited, 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, will serve as the Hong Kong share registrar.

Tax treatment has been detailed as follows: • Non-resident enterprise shareholders will be subject to a 10% withholding tax. • Non-resident individual shareholders—including Hong Kong residents—are also subject to a 10% withholding tax, unless modified by applicable treaties or regulations. • Mainland individual investors or securities investment funds holding H-shares through Shanghai-Hong Kong or Shenzhen-Hong Kong Stock Connect will incur a 20% withholding tax on the dividend.

No further details on exchange rates, default payment currency or timetable have been disclosed at this stage. The company emphasizes that it bears no liability for any disputes arising from the withholding mechanism or determinations of shareholder status.